Barium-Sulfate shortage — AU supply status & alternatives

Barium-Sulfate

—

In shortage · Australia

E-Z-Hd Barium Sulfate Powder For

In declared shortage · 🇦🇺 Australia & also short in🇳🇿 NZ

Critical shortage

Reading today’s signals…

✓ Can I substitute?

Yes — approved substitute available

TGA-approved overseas product

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

July 2026

Sponsor est. via TGA — may differ by brand

Product attributes reference data we hold

Active ingredient (INN)	Barium-Sulfate
Brand names	E-Z-Hd Barium Sulfate Powder For
Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

✓

Section 19A approval in force

An overseas-registered product has been approved for supply under Section 19A. See the website and search for the active ingredient: www.tga.gov.au/resources/section-19a-approvals

Shortage status by regulator official notices

🇦🇺

Australia

TGA · just now

Critical

🇳🇿

New Zealand

Pharmac · 12d ago

High

Verified timeline regulator events

🇳🇿 15 May 2026

high reported

🇳🇿 12 Mar 2026

high reported

🇳🇿 28 Nov 2025

high reported

🇦🇺 1 Oct 2013

critical reported

Sources official regulators

🇦🇺

TGA

verified just now

verify ↗

🇳🇿

Pharmac

verified 12d ago

verify ↗

Mederti Drug Report

Generated 4 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.